

Molebogeng X Rangaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2200236/publications.pdf>

Version: 2024-02-01

51
papers

3,114
citations

304743

22
h-index

265206

42
g-index

51
all docs

51
docs citations

51
times ranked

4008
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon- γ release assays: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 250-264. | 9.1 | 31 |
| 2 | Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 507-518. | 9.1 | 28 |
| 3 | Ending the tuberculosis syndemic: is COVID-19 the (in)convenient scapegoat for poor progress?. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 529-531. | 10.7 | 3 |
| 4 | Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis. <i>Lancet HIV</i> , the, 2022, 9, e233-e241. | 4.7 | 15 |
| 5 | Diagnostic accuracy of WHO screening criteria to guide lateral-flow lipoarabinomannan testing among HIV-positive inpatients: A systematic review and individual participant data meta-analysis. <i>Journal of Infection</i> , 2022, 85, 40-48. | 3.3 | 5 |
| 6 | Tests for tuberculosis infection: landscape analysis. <i>European Respiratory Journal</i> , 2021, 58, 2100167. | 6.7 | 35 |
| 7 | Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. <i>Lancet HIV</i> , the, 2021, 8, e8-e15. | 4.7 | 31 |
| 8 | Evaluating patient education resources for supporting treatment decisions in latent tuberculosis infection. <i>Health Education Journal</i> , 2021, 80, 513-528. | 1.2 | 3 |
| 9 | Randomised controlled trial to evaluate the effectiveness of using the RD-1-based C-Tb skin test as a replacement for blood-based interferon- γ release assay for detection of, and initiation of preventive treatment for, tuberculosis infection: RID-TB:Dx study protocol. <i>BMJ Open</i> , 2021, 11, e050595. | 1.9 | 0 |
| 10 | Tuberculosis Antigen-Specific T-Cell Responses During the First 6 Months of Antiretroviral Treatment. <i>Journal of Infectious Diseases</i> , 2020, 221, 162-167. | 4.0 | 9 |
| 11 | The Risk of Falsely Declaring Noninferiority of Novel Latent Tuberculosis Treatment in Large Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 511-513. | 5.6 | 0 |
| 12 | Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. <i>Nature Medicine</i> , 2020, 26, 1941-1949. | 30.7 | 58 |
| 13 | A user-centred design framework for mHealth. <i>PLoS ONE</i> , 2020, 15, e0237910. | 2.5 | 95 |
| 14 | Latent tuberculosis infection screening and treatment in congregate settings (TB FREE COREA): protocol for a prospective observational study in Korea. <i>BMJ Open</i> , 2020, 10, e034098. | 1.9 | 7 |
| 15 | Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 395-406. | 10.7 | 128 |
| 16 | What can 5G do for healthcare in Africa?. <i>Nature Electronics</i> , 2020, 3, 7-9. | 26.0 | 19 |
| 17 | A user-centred design framework for mHealth. , 2020, 15, e0237910. | | 0 |
| 18 | A user-centred design framework for mHealth. , 2020, 15, e0237910. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | A user-centred design framework for mHealth. , 2020, 15, e0237910. | | 0 |
| 20 | A user-centred design framework for mHealth. , 2020, 15, e0237910. | | 0 |
| 21 | A user-centred design framework for mHealth. , 2020, 15, e0237910. | | 0 |
| 22 | A user-centred design framework for mHealth. , 2020, 15, e0237910. | | 0 |
| 23 | Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. <i>Aids</i> , 2019, 33, 525-536. | 2.2 | 7 |
| 24 | Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus ¹ . <i>Clinical Infectious Diseases</i> , 2019, 69, 295-305. | 5.8 | 10 |
| 25 | Optimizing Tuberculosis Diagnosis in Human Immunodeficiency Virus ¹ -Infected Inpatients Meeting the Criteria of Seriously Ill in the World Health Organization Algorithm. <i>Clinical Infectious Diseases</i> , 2018, 66, 1419-1426. | 5.8 | 21 |
| 26 | Update in Tuberculosis and Nontuberculous Mycobacteria 2017. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1248-1253. | 5.6 | 14 |
| 27 | Mobile phone-based evaluation of latent tuberculosis infection: Proof of concept for an integrated image capture and analysis system. <i>Computers in Biology and Medicine</i> , 2018, 98, 76-84. | 7.0 | 14 |
| 28 | Eliminating tuberculosis in low-burden countries. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 3-3. | 1.2 | 5 |
| 29 | Development of a clinical prediction rule to diagnose <i>Pneumocystis jirovecii</i> pneumonia in the World Health Organization ¹ 's algorithm for seriously ill HIV-infected patients. <i>Southern African Journal of HIV Medicine</i> , 2018, 19, 851. | 0.9 | 6 |
| 30 | C-Tb: a latent tuberculosis skin test for the 21st century?. <i>Lancet Respiratory Medicine</i> , 2017, 5, 236-237. | 10.7 | 6 |
| 31 | The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges. <i>Journal of Infectious Diseases</i> , 2017, 216, S702-S713. | 4.0 | 170 |
| 32 | Measurement of Skin Induration Size Using Smartphone Images and Photogrammetric Reconstruction: Pilot Study. <i>JMIR Biomedical Engineering</i> , 2017, 2, e3. | 1.2 | 10 |
| 33 | Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2016, 30, 1279-1286. | 2.2 | 17 |
| 34 | Population tailored modification of tuberculosis specific interferon-gamma release assay. <i>Journal of Infection</i> , 2016, 72, 179-188. | 3.3 | 23 |
| 35 | Cytotoxic Mediators in Paradoxical HIV ¹ -Tuberculosis Immune Reconstitution Inflammatory Syndrome. <i>Journal of Immunology</i> , 2015, 194, 1748-1754. | 0.8 | 31 |
| 36 | Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. <i>Lancet</i> , 2015, 386, 2344-2353. | 13.7 | 156 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. <i>Clinical Microbiology Reviews</i> , 2014, 27, 3-20. | 13.6 | 662 |
| 38 | Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2014, 384, 682-690. | 13.7 | 229 |
| 39 | Improving the predictive value of interferon-gamma release assays: do our methods go far enough? [Editorial]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 1516-1516. | 1.2 | 0 |
| 40 | <i>Pneumocystis jirovecii</i> Pneumonia in Tropical and Low and Middle Income Countries: A Systematic Review and Meta-Regression. <i>PLoS ONE</i> , 2013, 8, e69969. | 2.5 | 44 |
| 41 | Plasmacytoid Dendritic Cells Infiltrate the Skin in Positive Tuberculin Skin Test Indurations. <i>Journal of Investigative Dermatology</i> , 2012, 132, 114-123. | 0.7 | 24 |
| 42 | Effect of Antiretroviral Therapy on the Diagnostic Accuracy of Symptom Screening for Intensified Tuberculosis Case Finding in a South African HIV Clinic. <i>Clinical Infectious Diseases</i> , 2012, 55, 1698-1706. | 5.8 | 48 |
| 43 | Corticosteroid-modulated Immune Activation in the Tuberculosis Immune Reconstitution Inflammatory Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 369-377. | 5.6 | 75 |
| 44 | Predictive value of interferon- γ release assays for incident active tuberculosis: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 45-55. | 9.1 | 441 |
| 45 | Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 19013-19017. | 7.1 | 174 |
| 46 | Dissection of Regenerating T-Cell Responses against Tuberculosis in HIV-infected Adults Sensitized by <i>Mycobacterium tuberculosis</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 674-683. | 5.6 | 60 |
| 47 | Novel Relationship between Tuberculosis Immune Reconstitution Inflammatory Syndrome and Antitubercular Drug Resistance. <i>Clinical Infectious Diseases</i> , 2009, 48, 667-676. | 5.8 | 93 |
| 48 | Neurologic Manifestations of Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome: A Case Series. <i>Clinical Infectious Diseases</i> , 2009, 48, e96-e107. | 5.8 | 163 |
| 49 | Clinical, Immunological, and Epidemiological Importance of Antituberculosis T Cell Responses in HIV-Infected Africans. <i>Clinical Infectious Diseases</i> , 2007, 44, 1639-1646. | 5.8 | 79 |
| 50 | Enhanced Ex Vivo Stimulation of <i>Mycobacterium tuberculosis</i> -Specific T Cells in Human Immunodeficiency Virus-Infected Persons via Antigen Delivery by the <i>Bordetella pertussis</i> Adenylate Cyclase Vector. <i>Vaccine Journal</i> , 2007, 14, 847-854. | 3.1 | 14 |
| 51 | QuantIFERON-TB Gold: state of the art for the diagnosis of tuberculosis infection?. <i>Expert Review of Molecular Diagnostics</i> , 2006, 6, 663-677. | 3.1 | 51 |